{Reference Type}: Randomized Controlled Trial
{Title}: Citicoline on the Barthel Index: Severe and moderate brain injury.
{Author}: Mahmoodkhani M;Aminmansour B;Shafiei M;Hasas M;Tehrani DS;
{Journal}: Indian J Pharmacol
{Volume}: 55
{Issue}: 4
{Year}: 2023 Jul-Aug
{Factor}: 2.833
{DOI}: 10.4103/ijp.ijp_570_21
{Abstract}: Traumatic brain injury (TBI) is a paramount factor in mortality and morbidity. The clinical trials conducted to investigate the efficacy of neuroprotective agents, such as citicoline, as a therapeutic alternative for TBI have presented divergent findings. Therefore, this study aimed to evaluate and compare citicoline's effect on the Barthel Index in patients with severe and moderate brain injury.<BR>The study is a randomized clinical trial. Patients in the case group (35 patients) were treated with citicoline and the control group (34 patients) received a placebo. Data were analyzed using SPSS 16 software.<BR>The results showed that changes in the Glasgow Coma Scale, changes in quadriceps muscle force score, Barthel Index score changes, achieving the status without intubation, and spontaneous breathing in patients treated with citicoline were not a statistically significant difference in the two groups (P > 0.05).<BR>Findings revealed that citicoline did not impact the recovery process of severe and moderate TBI patients.